Clinical trials: Vascularization
Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
This is a prospective pilot study to evaluate the usability and applicability of a self monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age Related Macular…
- Trial name
- NCT01542866
- Testing
- Health Management Tool (HMT)
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Choroid Neovascularization Secondary to Degenerative Myopia
A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV
This study is design to evaluate the effect of conbercept therapy on visual acuity and anatomic outcomes compared to sham injection and durability of response observed in subjects with choroid neovascularization secondary to…
- Trial name
- SHINY (NCT01809223)
- Testing
- conbercept, Fixed, conbercept, PRN
- Where
- 13 sites in China
- Volunteers
- 176 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Pathologic Myopia
High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)
This research project intends to observe patients with high myopia who show pathological retinal changes, in order to evaluate more data on the risk factors for developing mCNV within this research project population in Germany.
- Trial name
- HELP (NCT03070717)
- Testing
- Observation & Diagnosis
- Where
- 26 sites in Germany
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Choroidal Neovascularization
Episcleral Brachytherapy for the Treatment of Wet AMD
This is a prospective, multi-site, safety and feasibility study of the SalutarisMD SMD-DA system for retrobulbar minimally invasive episcleral brachytherapy device in patients receiving and not responding to anti-VEGF therapy for…
- Trial name
- NEAMES (NCT02988895)
- Testing
- episcleral brachytherapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Salutaris Medical Devices, Inc.
Macular Degeneration, Age-Related Maculopathies
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
This Phase 1 clinical research study will examine the safety and tolerability of an experimental gene transfer agent, AAV2-sFLT01, in patients with Neovascular Age-Related Macular Degeneration (AMD).
- Conditions
- Macular Degeneration, Age-Related Maculopathies, Age-Related Maculopathy, Maculopathies, Age-Related
- Trial name
- NCT01024998
- Testing
- AAV2-sFLT01
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Genzyme, a Sanofi Company
Age-related Macular Degeneration
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
The purpose of this study was to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received…
- Trial name
- FALCON (NCT04679935)
- Testing
- Brolucizumab
- Where
- 19 sites in Germany, Switzerland
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
Correlation Between Visual Field Defects on Foresee Preferential Hyperacuity Perimeter(PHP) and on Optical Coherence Tomography (OCT) in Patients With Choroidal Neovascularization (CNV)
Study come to investigate the correlation between visual fields (VF) defects map generated by preferential hyperacuity perimeter (PHP) and features of the choroidal neovascular lesions (CNV) demonstrated by Optical Coherence…
- Trial name
- PHP (NCT00692887)
- Testing
- PHP - Preferential Hyperacuity Perimeter (Foresee)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Notal Vision Ltd.
Macular Degeneration, Choroidal Neovascularization
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
The study will investigate the safety and feasibility of using the TheraSight(TM) Brachytherapy System for treatment of wet age-related macular degeneration (AMD).
- Trial name
- NCT00100087
- Testing
- Ocular Brachytherapy
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Theragenics Corporation
Macular Degeneration
A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world.
- Trial name
- NCT00089830
- Testing
- MSI-1256F (Squalamine Lactate)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Genaera Corporation
Wet Age-related Macular Degeneration
A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy
The objective of this clinical study is to evaluate the safety and feasibility of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) in patients with age related macular degeneration…
- Trial name
- ROSE (NCT00679445)
- Testing
- NeoVista Ophthalmic System
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NeoVista
Age-related Macular Degeneration
Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will receive injections of ranibizumab.
- Trial name
- MAKO (NCT02727881)
- Testing
- Squalamine lactate ophthalmic solution, 0.2%, ranibizumab
- Where
- 118 sites in United States
- Volunteers
- 230 people
- Sponsor
- Ohr Pharmaceutical Inc.
Pathological Myopia
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to…
- Trial name
- NCT01217944
- Testing
- Ranibizumab, Verteporfin PDT
- Where
- 74 sites in Austria, Canada and 18 more
- Volunteers
- 277 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal…
- Trial name
- NCT01940900
- Testing
- E10030, ranibizumab
- Where
- 121 sites in United States, Argentina and 9 more
- Volunteers
- 627 people
- Sponsor
- Ophthotech Corporation
Age-Related Macular Degeneration, Choroidal Neovascularization
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related…
- Trial name
- EMERALD (NCT00766337)
- Testing
- Sirolimus in combination with ranibizumab
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Santen Inc.
Age-related Macular Degeneration
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
- Trial name
- NCT02214628
- Testing
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Where
- 13 sites in United States
- Volunteers
- 101 people
- Sponsor
- Ophthotech Corporation
Macular Degeneration
A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration
A study to evaluate pazopanib tablets in male and female adults of non-child bearing potential with subfoveal CNV due to neovascular AMD. The goal is to assess safety and how well the subjects tolerate the drug.
- Trial name
- NCT01154062
- Testing
- Pazopanib
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Macular Degeneration
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5. Cand5, a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
- Trial name
- NCT00259753
- Testing
- Bevasiranib
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- OPKO Health, Inc.
Choroidal Neovascularization Secondary to Pathologic Myopia
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV).
- Trial name
- POYANG (NCT06176352)
- Testing
- Faricimab, Ranibizumab
- Where
- 63 sites in Australia, China and 9 more
- Volunteers
- 280 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-related Macular Degeneration
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration…
- Trial name
- IMAGINE (NCT04774926)
- Testing
- Brolucizumab
- Where
- 20 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Pigment Epithelial Detachment
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary…
- Trial name
- PED (NCT01334255)
- Testing
- iSONEP (sonepcizumab/LT1009)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Lpath, Inc.